OR WAIT null SECS
A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.
Ines Lains, MD, PhD, explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.
In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Mark Wieland, MD, noted that the Port Delivery System with ranibizumab provides drug delivery over an extended period.
Ajay Kuriyan, MD, discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting."
Dilsher Dhoot, MD, reported the results of the KESTREL and KITE in which brolucizumab was compared with aflibercept for treating diabetic macular edema.
Veeral Sheth, MD, presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.
Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.
Roger A. Goldberg, MD, MBA, noted that small misalignments in the plunger can lead to possible overdosing.
tPA treatment could provide benefits for patients with central retinal artery occlusion.
John Saharek, president of ImprimisRX, speaks with Modern Retina's David Hutton on three new products the company featured during the American Academy of Ophthalmology's 2021 annual meeting, including Moxi-Brom (moxifloxacin hydrochloride 0.5% and bromfenac sodium sesquihydrate 0.075%), Klarity-CL drops (cyclosporine 0.1% / loteprednol etabonate 0.2% ophthalmic suspension) and Tim-Brim-Dor-Bim (prednisolone acetate 1%, gatifloxacin 0.5%, bromfenac 0.075%).
Shady Awwad, MD, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.
Felipe Medeiros, MD, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.
VUITY, the first and only approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.
Denise Freitas, MD, reported that the ocular findings in infants with congenital Zika virus syndrome were similar among the affected infants and occurred frequently. The most prevalent of the findings was optic nerve pallor.
Nathan Hall, BS, MS, pointed out that an epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.